Novel genetic aberrations were found in 3% of tumors.
Malignant peritoneal mesothelioma has limited treatment options and no previously identified actionable mutations. To determine the molecular features of this rare orphan disease, investigators conducted a retrospective analysis of 88 archival peritoneal mesothelioma tumor specimens from a single institution and found 11 patients with ALK-immunohistochemistry (IHC)–positive staining.
In the 3 patients who were strongly ALK positive, ALK rearrangements were identified by fluorescent in situ hybridization. Next-generation sequencing determined the fusion partners to be ATG16L1, STRN, and TPM1. The 3 ALK rearranged patients were women, were younger than non-ALK rearranged patients (age, 36 vs. 62 years), and did not have the typical genetic abe…
Reviewing Author
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb